Cargando…

Glatiramer acetate treatment negatively regulates type I interferon signaling

OBJECTIVE: Glatiramer acetate (GA; Copaxone), a disease-modifying therapy for multiple sclerosis (MS), promotes development of anti-inflammatory (M2, type II) monocytes that can direct differentiation of regulatory T cells. We investigated the innate immune signaling pathways that participate in GA-...

Descripción completa

Detalles Bibliográficos
Autores principales:	Molnarfi, Nicolas, Prod'homme, Thomas, Schulze-Topphoff, Ulf, Spencer, Collin M., Weber, Martin S., Patarroyo, Juan C., Lalive, Patrice H., Zamvil, Scott S.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2015
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4645172/ https://www.ncbi.nlm.nih.gov/pubmed/26601118 http://dx.doi.org/10.1212/NXI.0000000000000179

Ejemplares similares

Glatiramer acetate immune modulates B-cell antigen presentation in treatment of MS
por: Häusler, Darius, et al.
Publicado: (2020)

Immunodominant T-cell epitopes of MOG reside in its transmembrane and cytoplasmic domains in EAE
por: Shetty, Aparna, et al.
Publicado: (2014)

MHC class II–dependent B cell APC function is required for induction of CNS autoimmunity independent of myelin-specific antibodies
por: Molnarfi, Nicolas, et al.
Publicado: (2013)

Glatiramer acetate treatment negatively regulates type I interferon signaling
Publicado: (2015)

Neither T-helper type 2 nor Foxp3(+) regulatory T cells are necessary for therapeutic benefit of atorvastatin in treatment of central nervous system autoimmunity
por: Weber, Martin S, et al.
Publicado: (2014)

Interferon–β Induces Hepatocyte Growth Factor in Monocytes of Multiple Sclerosis Patients
por: Molnarfi, Nicolas, et al.
Publicado: (2012)

Follow-on glatiramer acetate
por: Cohen, Jeffrey A., et al.
Publicado: (2018)

Laquinimod, a Quinoline-3-Carboxamide, Induces Type II Myeloid Cells That Modulate Central Nervous System Autoimmunity
por: Schulze-Topphoff, Ulf, et al.
Publicado: (2012)

Isoprenoids determine Th1/Th2 fate in pathogenic T cells, providing a mechanism of modulation of autoimmunity by atorvastatin
por: Dunn, Shannon E., et al.
Publicado: (2006)

Activation of human B cells negatively regulates TGF-β1 production
por: Molnarfi, Nicolas, et al.
Publicado: (2017)

Héritabilités et interactions génotype × régime pour le poids a huit semaines de poulets en présence de deux aliments
por: Mérat, P, et al.
Publicado: (1969)

Letter to the Editor Regarding: “Neurophysiological Assessments During Continuous Sedation Until Death Put Validity of Observational Assessments Into Question: A Prospective Observational Study”
por: Prod’homme, C., et al.
Publicado: (2022)

The effectiveness of interferon beta versus glatiramer acetate and natalizumab versus fingolimod in a Polish real-world population
por: Kapica-Topczewska, Katarzyna, et al.
Publicado: (2019)

Glatiramer acetate in the treatment of multiple sclerosis
por: Tselis, Alex, et al.
Publicado: (2007)

B-Cell Activity Predicts Response to Glatiramer Acetate and Interferon in Relapsing-Remitting Multiple Sclerosis
por: Tacke, Sabine, et al.
Publicado: (2021)

IgG glycan hydrolysis by EndoS inhibits experimental autoimmune encephalomyelitis
por: Benkhoucha, Mahdia, et al.
Publicado: (2012)

Demonstration of Equivalence of Generic Glatiramer Acetate and Copaxone(®)
por: Lipsky, Peter, et al.
Publicado: (2021)

Posterior intraprosthetic dislocation of cervical arthroplasty: illustrative case
por: Prod’homme, Marc, et al.
Publicado: (2021)

Restoration of Axon Conduction and Motor Deficits by Therapeutic Treatment with Glatiramer Acetate
por: Moore, Spencer, et al.
Publicado: (2014)

Differential glatiramer acetate treatment persistence in treatment-naive patients compared to patients previously treated with interferon
por: Fernández-Fournier, Mireya, et al.
Publicado: (2015)

Quantifying the risk of disease reactivation after interferon and glatiramer acetate discontinuation in multiple sclerosis: The VIAADISC score
por: Bsteh, Gabriel, et al.
Publicado: (2021)

Aquaporin 4-Specific T Cells in Neuromyelitis Optica Exhibit a Th17 Bias and Recognize Clostridium ABC Transporter
por: Varrin-Doyer, Michel, et al.
Publicado: (2012)

The role of glatiramer acetate in the early treatment of multiple sclerosis
por: Brandes, David W
Publicado: (2010)

Spasticity in multiple sclerosis and role of glatiramer acetate treatment
por: Meca-Lallana, Jose Eustasio, et al.
Publicado: (2015)

Glatiramer Acetate-associated Refractory Immune Thrombocytopenic Purpura
por: Sagy, Iftach, et al.
Publicado: (2016)

Physicochemical and Biological Examination of Two Glatiramer Acetate Products
por: Komlosh, Arthur, et al.
Publicado: (2019)

Bullous pemphigoid as an injection site reaction of glatiramer acetate
por: Baghbanian, Seyed Mohammad, et al.
Publicado: (2019)

Glatiramer Acetate Immunomodulation: Evidence of Neuroprotection and Cognitive Preservation
por: Kasindi, Arielle, et al.
Publicado: (2022)

An Immunomodulatory Peptide Dendrimer Inspired from Glatiramer Acetate
por: Erzina, Dina, et al.
Publicado: (2021)

Differential Transcription of SOCS5 and SOCS7 in Multiple Sclerosis Patients Treated with Interferon Beta or Glatiramer Acetate
por: Rojas-Morales, Emmanuel, et al.
Publicado: (2019)

Beneficial Effect of Melatonin Alone or in Combination with Glatiramer Acetate and Interferon β-1b on Experimental Autoimmune Encephalomyelitis
por: Ortíz, Genaro Gabriel, et al.
Publicado: (2022)

The Immunomodulatory Drug Glatiramer Acetate is Also an Effective Antimicrobial Agent that Kills Gram-negative Bacteria
por: Christiansen, Stig Hill, et al.
Publicado: (2017)

A Novel Minimally Invasive Reduction Technique by Balloon and Distractor for Intra-Articular Calcaneal Fractures: A Report of 2 Cases
por: Prod'homme, M., et al.
Publicado: (2018)

Epidural abscess related to Streptococcus mitis in a 57-year-old immunocompetent patient
por: Prod'homme, Marc, et al.
Publicado: (2021)

Adherence to glatiramer acetate treatment for multiple sclerosis: the Brazilian experience
por: de Oliveira, Tatiana de Melo Gomes, et al.
Publicado: (2008)

Glatiramer acetate desensitisation in multiple sclerosis patients - the case report
por: Novotna, Bronislava, et al.
Publicado: (2014)

Effectiveness of glatiramer acetate compared to other multiple sclerosis therapies
por: Izquierdo, Guillermo, et al.
Publicado: (2015)

Neuroprotection with glatiramer acetate: evidence from the PreCISe trial
por: Arnold, Douglas L., et al.
Publicado: (2013)

Metabolic response to glatiramer acetate therapy in multiple sclerosis patients
por: De Riccardis, Lidia, et al.
Publicado: (2016)

Demonstration of Biological and Immunological Equivalence of a Generic Glatiramer Acetate
por: D’Alessandro, Josephine, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_uardt3eris22mnq93ufoae9q1j